In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Oncomed Pharmaceuticals Inc. (NASDAQ:OMED) reported that Biotechnology Value Fund L P has picked up 1,843,484 of common stock as of 2017-05-31.
The acquisition brings the aggregate amount owned by Biotechnology Value Fund L P to a total of 1,843,484 representing less than 4.9% stake in the company.
For those not familiar with the company, OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.
A glance at Oncomed Pharmaceuticals Inc. (NASDAQ:OMED)’s key stats reveals a current market capitalization of 134.13 Million based on 37.62 Million shares outstanding and a price at last close of $3.41 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-05-25, Lasersohn picked up 34,614 at a purchase price of $3.37. This brings their total holding to 185,709 as of the date of the filing.
On the sell side, the most recent transaction saw Root unload 3,222 shares at a sale price of $3.70. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Oncomed Pharmaceuticals Inc. (NASDAQ:OMED) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.